Summary
The literature on fibrositis (fibromyalgia), which originated in the early years of the last century in the UK and proliferated there in the first half of this century, has since diminished there in the last 30 years or so, but has increased in Canada and the US. Criteria suggested for diagnosis have created a syndrome with no diagnostic tests, serological or radiological signs, arid no truly objective physical signs, but with predictable tender spots on pressure. The syndrome is largely, but not completely, confined to females, mostly of middle age; the symptoms include widespread aching of more than 3 months’ duration, disturbed sleep, morning fatigue and stiffness, a failure to respond satisfactorily to any one form of therapy and a tendency to persist over long periods, but without permanent tissue changes. Features of psychological disturbance are present in many patients but not in all or even the majority. Definition of the condition as a disorder of pain modulation — a pain amplification syndrome — would seem to fit the facts best. Most would agree that an abnormal response to stress is an important factor in the appearance of the syndrome, as other stress related disorders, such as the irritable bowel syndrome and tension headaches, may coexist. Response to therapy, whether physical or pharmacological, is on the whole unsatisfactory.
This type of patient has been well recognised in hospital clinic and general practice for many years. No signs of any arthritic or rheumatic disease are present and the diffuse pains complained of do not appear to be based on underlying organic disease, although emotional and psychic states (‘attitudes of mind’ rather than psychiatric disorders) probably play a major part in many cases.
Osteoarthritic or other chronic lesions may in some cases cause pain to be referred to muscles elsewhere in body and limb, and a lowered pain tolerance from different causes may magnify the symptoms, but it is probable that different factors operate in different cases and the clinical picture is not based on any single underlying pathological or psychiatric state.
Similar content being viewed by others
References
Ahles TA, Yunus MB, Riley SD, et al. Psychological factors associated with primary fibromyalgia syndromes. Arthritis and Rheumatism 27: 1101–1106, 1984
Balfour W. Observations with cases illustrative of a new, simple and expeditious mode of curing rheumatism and strains, J & C Muirhead, Edinburgh, 1816
Behan PO, Behan WMH, Bell EP. The post-viral fatigue syndrome: an analysis of the findings in 50 cases. Journal of Infection 4: 211–222, 1985
Bennett RM. Fibrositis: evolution of an enigma. Journal of Rheumatology 13: 676–678, 1986a
Bennett RM. Current issues concerning management of the fibrositis/fibromyalgia syndrome. American Journal of Medicine 81 (Suppl. 3A): 15–18, 1986b
Benytsson A, Henriksson K-G, Jorfeldt L, Kågedal B, Lennmarken C, et al. Primary fibromyalgia. Scandinavian Journal of Rheumatology 15: 340–347, 1986
Calabro JJ. Fibromyalgia (fibrositis) in children. American Journal of Medicine 81 (Suppl. 3A): 57–59, 1986
Campbell SM, Clark S, Tindall EA, Forehand ME, Bennett RM. Clinical characteristics of fibrositis: a ‘blinded’ controlled study of symptoms and tender points. Arthritis and Rheumatism 26: 817–824, 1983
Campbell SM, Gatter RA, Clark S, Bennett RM. A double blind study of cyclobenzaprine versus placebo in patients with fibrositis. Abstract D3. Arthritis and Rheumatism 27 (Suppl.): 576, 1984
Caro XJ. Immunofluorescent detection of IgG at the dermal-epidermal junction in patients with apparent primary fibrositis syndrome. Arthritis and Rheumatism 27: 1174–1179, 1984
Carrette S, McCain GA, Bell DA. A double blind study of amitriptyline versus placebo in patients with primary fibrositis (Abstract). Arthritis and Rheumatism 540: 158, 1985
Clark S, Campbell SM, Forehand ME, et al. Clinical characteristics of fibrositis. II. A blinded controlled study using standard psychological tests. Arthritis and Rheumatism 28: 132–137, 1985
Clark S, Tindall E, Bennett RM. A double-blind crossover trial of prednisone versus placebo in the treatment of fibrositis. Journal of Rheumatology 12: 980–983, 1985
Copeman WSC, Ackerman WL. ’Fibrositis’ of the back. Quarterly Journal of Medicine NS 13 (OS 37): 37–51, 1944
Dinerman H, Felson D, Goldenberg D. A randomised clinical trial of naproxen and amitriptyline in primary fibromyalgia (Abstract). Arthritis and Rheumatism 540: 159, 1985
Dinerman H, Goldenberg DL, Felson DT. A prospective evaluation of 118 patients with the fibromyalgia syndrome: prevalence of Raynaud’s phenomenon, Sicca syndrome, ANA low complement and Ig deposition at the dermo-epidermal junction. Journal of Rheumatology 13: 368–373, 1986
Ellman P, Savage OA, Wittkower E, Rodger TF. Fibrositis. Annals of the Rheumatic Diseases 3: 56–76, 1942
Felson DT, Goldenberg DL. The natural history of fibromyalgia. Arthritis and Rheumatism 29: 1522–1526, 1986
Gatter RA. Pharmacotherapeutics in fibrositis. American Journal of Medicine 81 (Suppl. 3A): 63–66, 1986
Goldenberg DL. Psychological studies in fibrositis. American Journal of Medicine 81 (Suppl. 3A): 67–70, 1986
Gowers WR. Lumbago: its lesions and analogues. British Medical Journal 1: 117–121, 1904
Hadler NM. A critical reappraisal of the fibrositis concept. American Journal of Medicine 81 (Suppl. 3A): 26–30, 1986
Hart FD. Occasional review: pain as an old friend. British Medical Journal 1: 1405–1407, 1979
Hart FD. Practical problems in rheumatology, p. 135, Martin Dunitz, London, 1983
Henderson DA, Shelokov A. Epidemic neuromyasthenia; clinical syndrome? New England Journal of Medicine 260: 814–818, 1959
Kalyan-Raman UP, Kalyan-Raman K, Yunus MB, Masi AT. Muscle pathology in primary fibromyalgia syndrome. Journal of Rheumatology 11: 808–814, 1984
Lund N, Bengtsson A, Thorborg P. Muscle tissue oxygen pressure in primary fibromyalgia. Scandinavian Journal of Rheumatology 15: 165–173, 1986
Lynn B, Kellgren JH. Pain. In Scott JT (Ed.) Copeman’s textbook of the rheumatic diseases, 6th ed., pp. 143–160, Churchill Livingstone, 1986
McEvedy CP, Beard AW. Royal free epidemic of 1955; a reconsideration. British Medical Journal 1: 7–11, 1970
McEvedy CP, Beard AW. Concept of benign myalgic encephalomyelitis. British Medical Journal 1: 11–15, 1970
Masi AT, Yunus MB. Concepts of illness in populations as applied to fibromyalgia syndrome. American Journal of Medicine 81 (Suppl. 3A): 93–98, 1986
Moldofsky H, Scarisbrick P, England R, et al. Musculo-skeletal symptoms and Non-REM sleep disturbance in patients with ‘fibrositis syndrome’ and healthy subjects. Psychosomatic Medicine 37: 341–351, 1975
Moldofsky H, Tullis C, Lue FA. Sleep related myoclonus in rheumatic pain modulation disorder (fibrositis syndrome). Journal of Rheumatology 13: 614–617, 1986
Molony RR, MacPeek DM, Schiffman PL, et al. Sleep, sleep apnoea and the fibromyalgia syndrome. Journal of Rheumatology 13: 797–800, 1986
Payne TC, Leavitt F, Gaison DC, Katz RS, Golden HE, et al. Fibrositis with psychologic disturbance. Arthritis and Rheumatism 25: 213–217, 1982
Reynolds MD. The definition of fibrositis. Arthritis and Rheumatism 25: 1506–1507, 1982
Richards AJ. Carpal tunnel syndrome and subsequent rheumatoid arthritis in the ‘fibrositis’ syndrome. Annals of the Rheumatic Diseases 43: 232–234, 1984
Scudamore C. A treatise on the nature and cure of rheumatism, Longmans, London, 1816
Simons DG. Muscle pain syndromes, part I. American Journal of Physical Medicine 54: 289–311,1975
Simons DG. Muscle pain syndromes, part II. American Journal of Physical Medicine 55: 15–42, 1976
Simons DG. Fibrositis/fibromyalgia: a form of myofascial trigger points? American Journal of Medicine 81 (Suppl. 3A): 93–98, 1986
Smythe HA. ‘Fibrositis’ as a disorder of pain modulation. Clinics in Rheumatic Diseases 5: 823–832, 1979
Smythe HA. Problems with the MMPI. Journal of Rheumatology 11: 417, 1984
Smythe HA. In Kelly et al. (Eds) Textbook of rheumatology, pp. 481–489, WB Saunders & Co., 1985
Stockman R. The causes, pathology and treatment of chronic rheumatism. Edinburgh Medical Journal NS 15: 107–116, 222–235, 1904
Stockman R. Rheumatism and arthritis, Green, Edinburgh, 1920
Straus SE, Tosato G, Armstrong G, et al. Persisting illness and fatigue in adults with evidence of Epstein-Barr virus infection. Annals of Internal Medicine 102: 7–16, 1985
Szasz TS. The psychiatric perspective on pain and its control. In Hart DF (Ed.) The treatment of chronic pain, pp. 30-61, Medical and Technical Publishing Co. Ltd, London, 1974 Szasz TS. Pain and pleasure, 2nd ed., Basic Books Inc., New York, 1975
Trout EF. Fibrositis. Journal of the American Geriatrics Society 16: 531–538, 1968
Wolfe F. Development of criteria in the diagnosis of fibrositis. American Journal of Medicine 81 (Suppl. 3A): 99–103, 1986
Wolfe F, Cathey MA. Prevalence of primary and secondary fibrositis. Journal of Rheumatology 10: 965–968, 1983
Wolfe F, Cathey MA, Kleinkeksel SM, Amos SP, Hoffman RG, et al. Psychological studies in primary fibrositis and fibrositis associated with rheumatoid arthritis. Journal of Rheumatology 11: 500–506,1984
Wysenbeck AJ, Mor F, Lurie Y, Weinberger A. Imipramine for the treatment of fibrositis: a therapeutic trial. Annals of the Rheumatic Diseases 44: 752–753, 1985
Yunus MB. Fibromyalgia syndrome: a need for uniform classification. Journal of Rheumatology 10: 841–844, 1983
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Hart, F.D. Fibrositis (Fibromyalgia). Drugs 35, 320–327 (1988). https://doi.org/10.2165/00003495-198835030-00006
Published:
Issue Date:
DOI: https://doi.org/10.2165/00003495-198835030-00006